Bifogade filer
BioInvent Q2 2025 - Narrowed Focus on BI-1206 and BI-1808
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Redeye via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
2025-08-27 12:35:00
Redeye comments on BioInvent’s Q2 report 2025. New positive results with BI-1206 in solid tumours and Non-Hodgkin lymphoma and with BI-1808 in T-cell lymphoma were presented. A pause of BI-1607 and BI-1910 was announced yesterday as the company focuses on late- to mid-stage development of BI-1206 and BI-1808.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/